Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Xigris Label Could Exclude Lower-Risk And Sickest Sepsis Patients

Executive Summary

Xigris, if approved, should be restricted to those severe sepsis patients defined by exclusion criteria in Lilly's pivotal trial, FDA's Anti-Infective Drug Advisory Committee recommended Oct. 16.
Advertisement

Related Content

Generic Biologics On FDA Fast Track?: “Follow-On” Process Under Debate
Generic Biologics On FDA Fast Track?: “Follow-On” Process Under Debate
Lilly Xigris Sepsis Benefit Defended By FDA In NEJM 
Lilly Xigris Sepsis Benefit Defended By FDA In NEJM 
APACHE II Sepsis Score Best Indicator Of Xigris Benefit, Labeling States
APACHE II Sepsis Score Best Indicator Of Xigris Benefit, Labeling States
Lilly Xigris Price Is $6,800 Per Dose; Sepsis Agent Clears FDA
Lilly Xigris Price Is $6,800 Per Dose; Sepsis Agent Clears FDA
Xigris Cmte. Invokes History Of Sepsis Failures; "Do It Right," Chair Says
Xigris Best-Case Label Would Be 400,000 Patients; User Fee Date Is Oct. 27
Advertisement
UsernamePublicRestriction

Register

PS038701

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel